Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.330 +0.070 (+1.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Why Is Cancer Player Candel Therapeutics Stock Trading Higher Today? ↗
Candel Therapeutics Inc (NASDAQ: CADL) released initial interim survival and immunological biomarker data from the ongoing phase 2 trial of CAN-2409 plus valacyclovir (prodrug) together with standard... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Candel Therapeutics's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Reveals Early Survival Data From Lung Cancer Trial ↗
Candel Therapeutics Inc (NASDAQ: CADL) announced updated activity data from its ongoing, open-label, phase 2 trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint... 
Via Benzinga
News headline image
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak... 
Via Benzinga
News headline image
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertise in the biopharmaceutical industry 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer ↗
Candel Therapeutics Inc (NASDAQ: CADL) announced new data from an ongoing phase 1 trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients... 
Via Benzinga
News headline image
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small... 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday. 
Via Benzinga
News headline image
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.